Tianjin Medical University Second Hospital

This study is testing whether a drug called toripalimab can prevent kidney cancer from coming back after surgery. All 100 participants, who have high-risk kidney cancer that was surgically removed, will receive the drug by IV every 3 weeks for about a year. Researchers will monit…